Please assess the completion status of the following clinical trial:

Trial Title: Trial of High-dose Urso in Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Chronic cholestatic disease of at least six months' duration.~* Serum alkaline phosphatase at least 1 ½ times the upper limits of normal.~* Retrograde, operative, percutaneous, or magnetic resonance cholangiography demonstrating intrahepatic and/or extrahepatic biliary duct obstruction, beading, or narrowing consistent with PSC within one year of the study entry.~* Liver biopsy in the previous one year which is available for review and compatible with the diagnosis of PSC. Compatible biopsy features include fibrous cholangitis, ductopenia with periportal inflammation and biliary fibrosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet that is identical (size, color, etc) to experimental ursodeoxycholic acid tablet.
- Ursodeoxycholic acid (Type: EXPERIMENTAL): Ursodeoxycholic acid 28-30 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).